The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:30 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #5. Prestige Brands Holdings, Inc. Hydralyte

Acquirer: Prestige Brands Holdings, Inc. (NYSE:PBH)
Acquiree: Hydralyte
Details: Prestige Brands Holdings, Inc. (NYSE:PBH) ("Prestige") today announced that it has closed the previously announced acquisition of Hydralyte from the Hydration Pharmaceuticals Trust of Victoria, Australia. Hydralyte is the leading over-the-counter oral rehydration brand in Australia, and will be marketed and sold through Care Pharmaceuticals ("Care"), Prestige's subsidiary in Australia.

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, Co. is engaged in the development, manufacturing, marketing, sales, and distribution of over-the-counter (OTC) health and personal care products. Co. conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare. Co.'s brands in the North American OTC Healthcare segment include Boudreaux's Butt Paste with products that include various diaper rash treatments and skin protectants. Co.'s brands in the International OTC Healthcare segment include Fess that relieves nasal and sinus congestion due to allergy, hay fever, colds and flu.

PBH SEC Filing Email Alerts Service


Open the PBH Page at The Online Investor »

Company Name: 
Prestige Consumer Healthcare Inc
Stock buyback: 
PBH buyback
Website: 
www.prestigeconsumerhealthcare.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding PBH: 
64
Total Market Value Held by ETFs: 
$747.31M
Total Market Capitalization: 
$2.96B
% of Market Cap. Held by ETFs: 
25.28%
 

Open the PBH Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PBH Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.50 out of 4)
46th percentile
(ranked lower than approx. 54% of all stocks covered)

Analysts' Target Price:
PBH Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 5 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.